We envision a future where people stay healthy for life.

Rejuvenate Biomed is a Belgian clinical-stage biomedical company founded in 2017 by Ann Beliën, PhD, after nearly two decades of experience with Janssen Pharmaceutical Companies of Johnson & Johnson. In six years, she has built a team of fourteen well-experienced drug development experts, enthusiastically engaged to make a difference in the longevity field. Rejuvenate Biomed's team has made exceptional progress by maturing the business to a clinical-stage company. By using its proprietary platforms, AI driven CombinAgeTM and in vivo C. elegans CelegAgeTM, Rejuvenate Biomed is generating multiple assets in the drug development pipeline, with lead RJx-01 currently in clinical Phase 1b.

  • August 2023

    First publication of animal data on RJx-01

    https://insight.jci.org/articles/view/168787

  • July 2023

    Introduction of CelegAge

    Proprietary and validated in vivo C. elegans drug discovery platform

  • May 2023

    Team expands to 14 innovators

  • March 2023

    Introduction of CombinAge

    Proprietary and validated AI-enabled in silico drug discovery platform

  • May 2022

    Ajit Shetty, PhD, appointed as Chair of the Board of Directors

  • April 2022

    Move to new office and lab at Health Campus, Diepenbeek

  • March 2022

    First clinical trial with RJx-01 initiated

  • October 2021

    € 15.7 million Series B financing round secured

  • March 2021

    € 3.2 million Series A financing round secured

  • August 2019

    € 1.16 million non-dilutive VLAIO funding

  • February 2019

    Key research collaboration with Marco Sandri, MD, PhD

    Professor at the Venetian Institute of Molecular Medicine

  • January 2019

    Key research collaboration with Rafael de Cabo, MD, PhD

    Professor at the NIA's Translational Gerontology Branch

  • August 2018

    € 460,000 non-dilutive VLAIO funding

  • November 2017

    Seed investment in place

  • October 2017

    Rejuvenate Biomed was founded